Opportunity Information: Apply for SOL OAA 13 000107
Apply for SOL OAA 13 000107
- The Agency for International Development in the health sector is offering a public funding opportunity titled "Morbidity Management and Disability Prevention for Blinding Trachoma and Lymphatic Filariasis" and is now available to receive applicants.
- This funding opportunity was created on Jul 8, 2013 and posted on Jul 8, 2013.
- Applicants must submit their applications by Aug 5, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $35,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $35,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- To be eligible for the Cooperative Agreement under this RFA, an organization must a)Be a U.S. or non U.S. based non governmental institution, for profit, non profit or private voluntary organization, or consortium of such organizations b)Have the managerial, technical, and institutional capacities to achieve the results outlined in this RFA c)The prime recipient or lead organization in the consortium must have a long standing and demonstrated history of providing quality surgical services and the complimenting technical assistance for trachoma.) and, d)Have the capacity to collaborate with other organizations/groups to mobilize resources and disseminate best practices. USAID welcomes applications from organizations which have not previously done business with USAID.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The USAID grant opportunity titled "Morbidity Management and Disability Prevention for Blinding Trachoma and Lymphatic Filariasis" is a health-focused funding announcement aimed at reducing the long-term suffering caused by two major neglected tropical diseases (NTDs): blinding trachoma and lymphatic filariasis (LF). While USAID supports control and elimination of seven NTDs that can be addressed through preventive chemotherapy, this particular opportunity centers on what happens after infection or repeated exposure has already led to serious, often lifelong disability. The core idea is that eliminating transmission alone is not enough; countries also need strong, accessible services that manage existing disease complications, prevent worsening disability, and improve quality of life for people already affected.
USAID planned to make one award through a Cooperative Agreement, with an estimated total funding level of up to $35,000,000 over five years (award ceiling also $35,000,000). Because the funding instrument is a Cooperative Agreement, the expectation is that USAID would remain substantially involved in the activity's direction and oversight, rather than simply providing funds with minimal engagement. The opportunity also includes a cost sharing or matching requirement, meaning the recipient would be expected to contribute resources beyond USAID funding, according to the specifics laid out in the full announcement.
Programmatically, the activity is designed to help endemic countries increase access to morbidity management and disability prevention (MMDP) services for blinding trachoma and LF. In practical terms, this means strengthening the parts of national NTD plans that address care for people with established disease and scaling up high-quality treatment and care services. For trachoma, the announcement highlights the need for demonstrated experience providing quality surgical services and related technical assistance, reflecting the importance of surgery in preventing blindness in advanced trachoma cases (for example, management of trichiasis to stop eyelashes from damaging the cornea). For lymphatic filariasis, MMDP generally includes clinical care and self-care support for chronic conditions such as lymphedema/elephantiasis and related complications, with an emphasis on preventing acute attacks, reducing progression, and improving daily functioning.
A major purpose of the award is to provide USAID's Bureau for Global Health and its NTD Program with implementation support that strengthens MMDP components within national strategies and helps countries meet elimination goals for blinding trachoma, particularly in countries already supported by USAID's NTD Program. The work described is not limited to direct service delivery; it explicitly includes helping countries plan, implement, and monitor the scale-up of services. That emphasis signals a systems-oriented approach: building national capacity, improving service quality, standardizing approaches, tracking coverage and outcomes, and ensuring that morbidity services are integrated into broader NTD programming rather than treated as an optional add-on.
Eligibility for the award was open to U.S. or non-U.S. non-governmental entities, including for-profit, non-profit, and private voluntary organizations, as well as consortia of such organizations. Applicants needed to demonstrate the managerial, technical, and institutional capacity to achieve the results envisioned in the announcement. A notable requirement is that the prime recipient or lead organization must have a long-standing, demonstrated record of delivering quality trachoma surgical services along with the complementary technical assistance, which indicates that USAID expected the lead to bring deep, proven expertise rather than building that capability from scratch during the project. In addition, applicants needed the ability to collaborate with other organizations or groups to mobilize resources and share best practices, reinforcing that this activity was intended to coordinate across partners and country systems. USAID also explicitly welcomed applications from organizations that had not previously done business with the agency, signaling openness to new implementers if they could meet the technical and operational bar.
Administratively, this was a discretionary funding opportunity in the health category, posted July 8, 2013, with an original and current closing date of August 5, 2013, and an archive date of December 31, 2013. The opportunity was identified by Funding Opportunity Number SOL-OAA-13-000107. The listed point of contact for access issues with the full announcement was Saurabh Vasudeva, Agreement Specialist (202-527-4195, svasudeva@usaid.gov).
FAQs: USAID - Morbidity Management and Disability Prevention for Blinding Trachoma and Lymphatic Filariasis
What is the title of this USAID funding opportunity?
The opportunity is titled "Morbidity Management and Disability Prevention for Blinding Trachoma and Lymphatic Filariasis."
What is the main goal of this opportunity?
The goal is to reduce long-term suffering and disability caused by blinding trachoma and lymphatic filariasis (LF) by expanding access to morbidity management and disability prevention (MMDP) services. The emphasis is on caring for people who already have established disease complications, not only stopping transmission.
Which diseases does the opportunity focus on?
It focuses on two neglected tropical diseases (NTDs): blinding trachoma and lymphatic filariasis (LF).
Why is USAID emphasizing morbidity management and disability prevention (MMDP) instead of only eliminating transmission?
The opportunity reflects the idea that eliminating transmission alone is not enough. Even after infection or repeated exposure ends, many people already live with serious, often lifelong complications. MMDP services are intended to manage existing disease, prevent disability from getting worse, and improve quality of life.
How does this opportunity relate to USAID work on other NTDs?
USAID supports control and elimination of seven NTDs that can be addressed through preventive chemotherapy, but this particular funding announcement centers on the care and services needed after disease has already caused disability, specifically for trachoma and LF.
What type of award does USAID plan to make?
USAID planned to make one award through a Cooperative Agreement.
What does it mean that the instrument is a Cooperative Agreement?
A Cooperative Agreement indicates that USAID is expected to remain substantially involved in the activity's direction and oversight, rather than only providing funding with minimal engagement.
How many awards were planned under this announcement?
USAID planned to make one award.
What is the estimated total funding amount and duration?
The estimated total funding level is up to $35,000,000 over five years.
What is the award ceiling?
The award ceiling is $35,000,000.
Is cost sharing or matching required?
Yes. The opportunity includes a cost sharing or matching requirement, meaning the recipient is expected to contribute resources beyond USAID funding, consistent with the full announcement's specifics.
What kinds of activities is the program designed to support?
The activity is designed to help endemic countries increase access to MMDP services for blinding trachoma and LF. This includes strengthening the MMDP portions of national NTD plans and scaling up high-quality treatment and care services.
Is the work limited to direct service delivery?
No. The announcement explicitly includes supporting countries to plan, implement, and monitor the scale-up of services. It signals a systems-oriented approach that builds national capacity and improves service quality and tracking.
What does "systems-oriented" support mean in this opportunity?
Based on the description, it includes building national capacity, improving and standardizing service quality, tracking coverage and outcomes, and ensuring morbidity services are integrated into broader NTD programming rather than treated as an optional add-on.
What is the specific emphasis for trachoma under this opportunity?
For trachoma, the announcement highlights the need for demonstrated experience providing quality surgical services and related technical assistance. This reflects the central role of surgery in preventing blindness in advanced trachoma cases.
What trachoma-related surgical issue is referenced as an example?
The announcement references management of trichiasis, where eyelashes can damage the cornea, and surgery can help prevent blindness in advanced cases.
What does MMDP typically include for lymphatic filariasis (LF)?
For LF, MMDP generally includes clinical care and self-care support for chronic conditions such as lymphedema/elephantiasis and related complications, with an emphasis on preventing acute attacks, reducing progression, and improving daily functioning.
Who within USAID is this award intended to support?
A major purpose is to provide USAID's Bureau for Global Health and its NTD Program with implementation support to strengthen MMDP components within national strategies and help countries meet elimination goals for blinding trachoma.
Which countries are a particular focus of the work described?
The description highlights support for countries already supported by USAID's NTD Program, particularly in relation to meeting elimination goals for blinding trachoma.
Who was eligible to apply?
Eligibility was open to U.S. or non-U.S. non-governmental entities, including for-profit, non-profit, and private voluntary organizations, as well as consortia of such organizations.
Are for-profit organizations eligible?
Yes. For-profit entities are included among the eligible non-governmental applicants.
Are non-U.S. organizations eligible?
Yes. Both U.S. and non-U.S. non-governmental entities were eligible.
Can a consortium apply?
Yes. Consortia of eligible organizations were included in the eligibility description.
What capacity did applicants need to demonstrate?
Applicants needed to demonstrate managerial, technical, and institutional capacity to achieve the results envisioned in the announcement.
Was there a specific requirement for the prime (lead) organization?
Yes. The prime recipient or lead organization must have a long-standing, demonstrated record of delivering quality trachoma surgical services along with complementary technical assistance.
Does the opportunity expect collaboration with other organizations?
Yes. Applicants needed the ability to collaborate with other organizations or groups to mobilize resources and share best practices, indicating a strong coordination expectation.
Did USAID welcome first-time USAID applicants?
Yes. USAID explicitly welcomed applications from organizations that had not previously done business with the agency, as long as they could meet the technical and operational requirements.
What is the funding opportunity number?
The Funding Opportunity Number is SOL-OAA-13-000107.
What is the funding category?
This was a discretionary funding opportunity in the health category.
When was the opportunity posted?
The opportunity was posted on July 8, 2013.
What was the closing date?
The original and current closing date was August 5, 2013.
When was the opportunity archived?
The archive date was December 31, 2013.
Who was the point of contact listed for access issues with the full announcement?
The listed point of contact for access issues was Saurabh Vasudeva, Agreement Specialist.
What contact details were provided for the point of contact?
The phone number provided was 202-527-4195, and the email address provided was svasudeva@usaid.gov.
Browse more opportunities from the same agency: Agency for International Development
Browse more opportunities from the same category: Health
Next opportunity: City of Rocks National Reserve Annual Management Funding
Previous opportunity: Administer Internship Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for SOL OAA 13 000107
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (SOL OAA 13 000107) also looked into and applied for these:
| Funding Opportunity |
|---|
| Secondary Analyses of Alcohol and Chronic Disease (R21) Apply for PA 13 251 Funding Number: PA 13 251 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Secondary Analyses of Alcohol and Chronic Disease (R01) Apply for PA 13 260 Funding Number: PA 13 260 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Secondary Analyses of Alcohol and Chronic Disease (R03) Apply for PA 13 261 Funding Number: PA 13 261 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Dose Response and Efficacy Studies on the Effects of Vitamin D Supplementation on Functional Outcomes in Elderly (U01) Apply for RFA AG 14 001 Funding Number: RFA AG 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implications of New Digital Media Use for Underage Drinking, Drinking Related Behaviors, and Prevention Research (R21) Apply for PA 13 263 Funding Number: PA 13 263 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Implications of New Digital Media Use for Underage Drinking, Drinking Related Behaviors, and Prevention Research (R01) Apply for PA 13 262 Funding Number: PA 13 262 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel NeuroAIDS Therapeutics Integrated Preclinical/Clinical Program (P01) Apply for PAR 13 267 Funding Number: PAR 13 267 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Developing a Point of Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings SBIR (R43/ R44) Apply for RFA HL 14 010 Funding Number: RFA HL 14 010 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| NEI Center Core Grants for Vision Research (P30) Apply for PAR 13 269 Funding Number: PAR 13 269 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health Promotion and Disease Prevention Research Centers Apply for RFA DP 14 001 Funding Number: RFA DP 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $900,000 |
| Urban Indian Education and Research Organization Cooperative Agreement Program Apply for HHS 2013 IHS OUIHP 0001 Funding Number: HHS 2013 IHS OUIHP 0001 Agency: Indian Health Service Category: Health Funding Amount: $800,000 |
| NINDS Clinical Trial Methods in Clinical Neurological Disorders Course (R25) Apply for RFA NS 14 001 Funding Number: RFA NS 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Researcher Training and Workforce Development in Methods and Standards for Conducting Patient Centered Outcomes Research Studies (R25) Apply for RFA HS 14 004 Funding Number: RFA HS 14 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Instrument Development for Biomedical Applications (R21) Apply for RFA GM 14 014 Funding Number: RFA GM 14 014 Agency: National Institutes of Health Category: Health Funding Amount: $175,000 |
| Mentored Research Scientist Development Award (K01) Apply for PAR 13 245 Funding Number: PAR 13 245 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Affordable Care Act Maternal, Infant and Early Childhood Home Visiting Formula Grant Program Apply for HRSA 13 278 Funding Number: HRSA 13 278 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Blood Pressure Measurement Technologies for Low Resource Settings in the U.S. and India (U01) Apply for RFA EB 13 001 Funding Number: RFA EB 13 001 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Emerging Priorities in Reproductive, Maternal and Newborn Health Apply for APS OAA 13 000005 Funding Number: APS OAA 13 000005 Agency: Agency for International Development Category: Health Funding Amount: $9,000,000 |
| National Center for Construction Safety and Health Research and Translation (U60) Apply for RFA OH 13 001 Funding Number: RFA OH 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,750,000 |
| Clinical Trial of a Multifactorial Fall Injury Prevention Strategy in Older Persons (U01) Apply for RFA AG 14 009 Funding Number: RFA AG 14 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "SOL OAA 13 000107", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.